TY - JOUR
T1 - 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions
T2 - a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI)
AU - Lip, Gregory Y. H.
AU - Collet, Jean-Phillippe
AU - Haude, Michael
AU - Byrne, Robert
AU - Chung, Eugene H.
AU - Fauchier, Laurent
AU - Halvorsen, Sigrun
AU - Lau, Dennis
AU - Lopez-Cabanillas, Nestor
AU - Lettino, Maddalena
AU - Marin, Francisco
AU - Obel, Israel
AU - Rubboli, Andrea
AU - Storey, Robert F.
AU - Valgimigli, Marco
AU - Huber, Kurt
AU - Potpara, Tatjana
AU - Lundqvist, Carina Blomstrom
AU - Crijns, Harry
AU - Steffel, Jan
AU - Heidbuchel, Hein
AU - Stankovic, Goran
AU - Airaksinen, Juhani
AU - Ten Berg, Jurrien M.
AU - Capodanno, Davide
AU - James, Stefan
AU - Bueno, Hector
AU - Morais, Joao
AU - Sibbing, Dirk
AU - Rocca, Bianca
AU - Hsieh, Ming-Hsiung
AU - Akoum, Nazem
AU - Lockwood, Deborah J.
AU - Gomez Flores, Jorge Rafael
AU - Jardine, Ronald
AU - ESC Scientific Document Group
PY - 2019/2
Y1 - 2019/2
N2 - In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.
AB - In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.
KW - European Heart Rhythm Association
KW - Consensus document
KW - Position paper
KW - Atrial fibrillation
KW - Acute coronary syndrome
KW - Coronary artery disease
KW - Myocardial infarction
KW - Percutaneous coronary intervention
KW - Stent
KW - Antithrombotic therapy
KW - Antiplatelet agents
KW - Anticoagulation
KW - Vitamin K antagonists
KW - Non-vitamin K antagonist oral anticoagulants
KW - Low molecular weight heparin
KW - Parenteral anticoagulants
KW - Left atrial appendage occlusion
KW - Stroke
KW - Thromboembolism
KW - Thrombosis
KW - Bleeding
KW - AORTIC-VALVE IMPLANTATION
KW - ACUTE MYOCARDIAL-INFARCTION
KW - DUAL ANTIPLATELET THERAPY
KW - BLEEDING RISK SCORES
KW - VITAMIN-K ANTAGONIST
KW - ST-SEGMENT ELEVATION
KW - HAS-BLED SCORES
KW - UNINTERRUPTED ORAL ANTICOAGULATION
KW - ELUTING STENT IMPLANTATION
KW - BARE-METAL STENTS
U2 - 10.1093/europace/euy174
DO - 10.1093/europace/euy174
M3 - Article
VL - 21
SP - 192
EP - 193
JO - EP Europace
JF - EP Europace
SN - 1099-5129
IS - 2
ER -